Boehringer Ingelheim provides new home for biocrea's BBB-crossing PDE2 inhibitors
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has acquired an early-stage programme investigating the development of phosphodiesterase (PDE) inhibitors that can cross the blood-brain barrier (BBB) from biocrea of Germany. The deal includes biocrea's most advanced compound, BCA909, a preclinical candidate that represents a new approach to treating cognitive impairment in diseases such as Alzheimer's.